|
Morepen Laboratories has developed and added three
blockbuster drugs to its portfolio of Active Pharmaceutical Ingredients (APIs) for sale in
domestic and global markets. The three bulk drugs / APIs are Rivaroxaban (trade name- Xarelto),
Vildagliptin (trade names- Galvus, Zomelis) and UDCA (Ursodeoxycholic Acid).
While two products Rivaroxaban and Vildagliptin will augment Morepen's presence in the
Cardiac and Diabetic segments respectively, the third product UDCA will cater to the Liver
segment.
The current global market size for Rivaroxaban, a powerful anticoagulant (blood thinner), is
$7.1 9Billion (Rs. 51,000 cores) and that of Vildagliptin, which is a strong oral Anti-diabetic
drug used for the treatment of type 2 diabetes, is $1.28 Billion (Rs. 9,000 cores). The global
market size for Rivaroxaban is likely to touch $9.00 Billion (Rs. 64,000 crore) by year 2023
and that of Yildagliptin $1.35 Billion (Rs. 9,600 crore) by 2021 . Morepen Labs will initially
target patent free markets for these two drugs globally. The Drug Master File (DMF) for
regulatory markets like US etc will be filed within the next 12 months' time frame.
|